CoChat

Both Continuous Subcutaneous Insulin Infusion and a Multiple Daily Insulin Injection Regimen With Glargine as Basal Insulin Are Equally Better Than Traditional Multiple Daily Insulin Injection Treatment

Lepore, Giuseppe, Dodesini, Alessandro R., Nosari, Italo, Trevisan, Roberto · 2003 · Diabetes Care
Cited by 55

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Diabetes Control and Complications Trial results showed that strict metabolic control may substantially reduce the risk of long-term microvascular complications (1). Over the study period, which averaged 7 years, the mean HbA1c level in the intensive group treatment was 7.2%. Current guidelines of treatment for type 1 diabetes propose a goal of HbA1c <7% (2). Nevertheless, in usual clinical practice, an acceptable metabolic control is achieved in a too low proportion of patients, even under multiple daily insulin injections (MDIs) (3). A recent meta-analysis of randomized trials concluded that continuous subcutaneous insulin infusion (CSII) permits a small improvement in blood glucose control with respect to MDIs (4). Glargine insulin is a human insulin analog that might mimic the effects of CSII at single basal infusion rate. Preliminary studies indicate that glargine may reduce the incidence of hypoglycemia and fasting blood glucose compared with NPH (5). Whether an MDI treatment with glargine as long-acting insulin may offer similar results to those obtained with CSII is still unknown (6). For this purpose, …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.26.4.1321

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 55

Metadata

Authors
Lepore, G., Dodesini, A. R., Nosari, I., & Trevisan, R.
Venue
Diabetes Care
Published
2003-04-01
Volume
26
Issue
4
Pages
1321-1322
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2125148407
Cited by
55
References
1
FWCI
4.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Both Continuous Subcutaneous Insulin Infusion and a Multiple Daily Insulin Injection Regimen With Glargine as Basal Insulin Are Equally Better Than Traditional Multiple Daily Insulin Injection Treatment. https://app.cochat.ai/papers/10.2337/diacare.26.4.1321
The paper
Lepore, G., Dodesini, A. R., Nosari, I., & Trevisan, R. (2003). Both Continuous Subcutaneous Insulin Infusion and a Multiple Daily Insulin Injection Regimen With Glargine as Basal Insulin Are Equally Better Than Traditional Multiple Daily Insulin Injection Treatment. Diabetes Care. https://doi.org/10.2337/diacare.26.4.1321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.